This study aimed to evaluate the prognostic value of pre-treatment NLR in patients with oropharyngeal cancer.
Patients who completed definitive radiotherapy (RT) for oropharyngeal cancer and had blood counts taken pre-RT from 2002 to 2013 were included. NLR was calculated as total neutrophil/lymphocytes. Survival rates were estimated using the Kaplan–Meier method. Univariable and multivariable analyses were conducted with linear and Cox regression methods. NLR was analysed posteriori and dichotomised on the discovered median.
Eight hundred and forty-eight patients were analysed. The median pre-RT NLR was 3. Patients with NLR of <3 had improved overall survival (OS) than those with NLR ≥ 3 (5-year OS 85 vs 74%, p < 0.0001). OS differences remained significant when stratified according to HPV status (HPV-positive p = 0.011; HPV-negative p = 0.003). Freedom from any recurrence (FFR), locoregional control (LRC) and freedom of distant recurrence (FDR) were better in those with NLR < 3. The negative impact of elevated pre-RT NLR on OS (HR = 1.64, p = 0.001), FFR (HR = 1.6, p = 0.006) and LRC (HR = 1.8, p = 0.005) remained significant on multivariable analysis.
Pre-RT NLR is an independent prognostic factor in patients with oropharyngeal cancer regardless of HPV status. Patients with lower NLR had more favourable OS and disease control.
Subscribe to Journal
Get full journal access for 1 year
only $20.79 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Chaturvedi, A. K., Anderson, W. F., Lortet-Tieulent, J., Curado, M. P., Ferlay, J., Franceschi, S. et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J. Clin. Oncol. 31, 4550–4559 (2013).
Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002).
Conteduca, V., Crabb, S. J., Jones, R. J., Caffo, O., Elliott, T., Scarpi, E. et al. Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS ONE 11, e0158952 (2016).
Kim, T. W., Lee, J. H., Shim, K. H., Choo, S. H., Choi, J. B., Ahn, H. S. et al. Prognostic significance of preoperative and follow-up neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with non-metastatic clear cell renal cell carcinoma. Investig. Clin. Urol. 60, 14–20 (2019).
Choi, J. H., Suh, Y. S., Choi, Y., Han, J., Kim, T. H., Park, S. H. et al. Comprehensive analysis of the neutrophil-to-lymphocyte ratio for preoperative prognostic prediction nomogram in gastric cancer. World J. Surg. 42, 2530–2541 (2018).
Mason, M., Maurice, C., McNamara, M. G., Tieu, M. T., Lwin, Z., Millar, B. A. et al. Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. J. Neurooncol. 132, 463–471 (2017).
Kuo, C., Hsueh, W. T., Wu, Y. H., Yang, M. W., Cheng, Y. J., Pao, T. H. et al. The role of pretreatment serum neutrophil-to-lymphocyte ratio in hypopharyngeal cancer treated with definitive chemoradiotherapy: a pilot study. Sci. Rep. 9, 1618 (2019).
Templeton, A. J., McNamara, M. G., Seruga, B., Vera-Badillo, F. E., Aneja, P., Ocana, A. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl Cancer Inst. 106, dju124 (2014).
Takenaka, Y., Oya, R., Kitamiura, T., Ashida, N., Shimizu, K., Takemura, K. et al. Prognostic role of neutrophil-to-lymphocyte ratio in head and neck cancer: a meta-analysis. Head Neck 40, 647–655 (2018).
Charles, K. A., Harris, B. D., Haddad, C. R., Clarke, S. J., Guminski, A., Stevens, M. et al. Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients. BMC Cancer 16, 124 (2016).
Cho, Y. Kim, J. W., Yoon, H. I., Lee, C. G., Keum, K. C. & Lee, I. J. The prognostic significance of neutrophil-to-lymphocyte ratio in head and neck cancer patients treated with radiotherapy. J. Clin. Med. https://doi.org/10.3390/jcm7120512 (2018).
So, Y. K., Lee, G., Oh, D., Byeon, S., Park, W. & Chung, M. K. Prognostic role of neutrophil-to-lymphocyte ratio in patients with human papillomavirus-positive oropharyngeal cancer. Otolaryngol. Head Neck Surg. 159, 303–309 (2018).
Chandrasekara, S., Davis, S., Thomson, P. & Haydon, A. High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy. Asia Pac. J. Clin. Oncol. 14, e442–e447 (2018).
Bojaxhiu, B., Templeton, A. J., Elicin, O., Shelan, M., Zaugg, K., Walser, M. et al. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation. Radiat. Oncol. 13, 216 (2018).
Kim, D. Y., Kim, I. S., Park, S. G., Kim, H., Choi, Y. J. & Seol, Y. M. Prognostic value of posttreatment neutrophil-lymphocyte ratio in head and neck squamous cell carcinoma treated by chemoradiotherapy. Auris Nasus Larynx 44, 199–204 (2017).
Cho, J. K., Kim, M. W., Choi, I. S., Moon, U. Y., Kim, M. J., Sohn, I. et al. Optimal cutoff of pretreatment neutrophil-to-lymphocyte ratio in head and neck cancer patients: a meta-analysis and validation study. BMC Cancer 18, 969 (2018).
Lin, A. J., Gang, M., Rao, Y. J., Campian, J., Daly, M., Gay, H. et al. Association of posttreatment lymphopenia and elevated neutrophil-to-lymphocyte ratio with poor clinical outcomes in patients with human papillomavirus-negative oropharyngeal cancers. JAMA Otolaryngol. Head Neck Surg. 145, 413–421 (2019).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Goldenberg, D., Begum, S., Westra, W. H., Khan, Z., Sciubba, J., Pai, S. I. et al. Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head Neck 30, 898–903 (2008).
Tang, C., Fuller, C. D., Garden, A. S., Awan, M. J., Colen, R. R., Morrison, W. H. et al. Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: quantitative image analysis of post-radiotherapy response. Oral. Oncol. 51, 195–201 (2015).
Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883–899 (2010).
Ethics approval and consent to participate
This study was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center. Informed consent was waived. This study was performed in accordance with the Declaration of Helsinki.
Consent to publish
Data will be available on request.
The authors declare no competing interests.
S.P.N. is funded by the Australian Postgraduate Award, the Royal Australian and New Zealand College of Radiologists (RANZCR) Research Grant and the Radiological Society of North America (RSNA) Fellow Grant. C.D.F. was supported by Andrew Sabin Family Fellowship. C.D.F. received funding support from the National Institutes of Health (NIH)/National Institute for Dental and Craniofacial Research (NIDCR) (1R01DE025248-01/R56DE025248-01). C.D.F. was previously funded via the National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QuBBD) Grant (NSF DMS-1557679) and is currently supported by the NIH National Cancer Institute (NCI)/Big Data to Knowledge (BD2K) Program (1R01CA214825-01), the NIH/NCI Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Research Program Career Development Award (P50CA097007-10); the NCI Paul Calabresi Clinical Oncology Program Award (K12 CA088084-06); a General Electric Healthcare/MD Anderson Center for Advanced Biomedical Imaging In-Kind Award; an Elekta AB/MD Anderson Department of Radiation Oncology Seed Grant; the Center for Radiation Oncology Research (CROR) at MD Anderson Cancer Center Seed Grant and the MD Anderson Institutional Research Grant (IRG) Program. C.D.F. has received speaker travel funding from Elekta AB. This study was supported in part by the NIH/NCI Cancer Center Support (Core) Grant CA016672 to The University of Texas MD Anderson Cancer Center (P30 CA016672). F.M.J. has received research funding from PIQUR Therapeutics and Trovagene. E.M.S. has a research award from Roche Diagnostics supporting HPV testing of oral rinse and mucosal swab samples on the clinical trial for HPV-related cancers screening in men (HOUSTON study).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
About this article
Cite this article
Ng, S.P., Bahig, H., Jethanandani, A. et al. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. Br J Cancer (2020). https://doi.org/10.1038/s41416-020-01106-x